CAR-T therapy has been a major innovation in cancer treatment, revolutionizing the care of patients with various forms of leukaemia. Nonetheless, 7-25% of patients with B-cell acute lymphoblastic leukaemia relapse after a period of therapy. Researchers described the mechanisms through which the tumour escapes the treatment and returns stronger than before.